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workbook. Results: Of the 71 STAs published, ACDs were produced for 60 technolo-
gies, while 11 (15%) proceeded straight to FAD. All submissions which proceeded 
directly to FAD were recommended (full or optimised) in the final guidance. Twelve 
STAs (20%) received a “minded no” at ACD; however, 11 of these (92%) were reversed 
within the FAD on the basis of additional data provided by the manufacturers in 
the form of economic analyses (n= 5) or patient access schemes (PAS) (n= 6). Of the 
35 “not recommended” at ACD, 15 (43%) were ultimately recommended within the 
FAD through the introduction or revision of a PAS and/or submission of additional 
analyses. ConClusions: If manufacturers can demonstrate a robust clinical and 
economic argument in their initial submission the chances of a FAD being produced 
without the requirement of an ACD are greatly increased. Furthermore, ACD deci-
sions can also be overturned; technologies which receive a “minded no” or “not 
recommended” at ACD stage can achieve a recommendation at FAD by presenting 
additional analyses or introducing/modifying a PAS.
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objeCtives: In 2006, the EUnetHTA project was launched. One of its main strategic 
objectives was to strengthen the link between HTA and health care policy making 
in the EU. Seven years after EUnetHTA establishment, the objective of this study 
was to compare HTA agencies’ assessments in France, Germany and UK, focusing 
on method and outcomes. Methods: Scope of the study was all the products 
getting a positive opinion from CHMP during two years, starting at January 1, 2011. 
Comparison between assessments was made for products assessed by the three 
HTA agencies: IQWiG, NICE, and HAS. Results: A total of 87 drugs were included in 
this study. 11 (13%) have been assessed by the three agencies. Among these drugs, 
more than 50% (6) were cancer treatment. HAS was the first to assess drug in 6 cases 
(mean delay between CHMP positive opinion and assessment: 223 days), followed 
closely by IQWiG (242 days), then by NICE (354 days). IQWiG segmented the patient 
population defined by the manufacturer into different sub-populations in 6 assess-
ments, HAS in 2, NICE never. NICE was the only agency who did not recommend a 
drug for cost-effectiveness reasons (2 assessments). In three assessments, IQWiG 
concluded that there was no benefit proven for the whole population; regarding 
the same drugs, HAS concluded there was minor improvement in actual benefit 
twice. ConClusions: Some major trends emerge in the assessments studied: use 
of indirect comparisons, added therapeutic value weighted by severity and fre-
quency of side effects and uncertainty. Nevertheless, comparator choices, perception 
of clinical benefits and risks, budget impact and overall method still differ between 
the three HTA agencies studied, leading to different outcomes for drugs assessed.
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objeCtives: To examine whether the Delphi method can provide a convenient 
tool for selecting medical technologies for inclusion in the National List of Health 
Services (NLHS) in Israel under a pre-defined budget constraint. Methods: The 
Delphi method was applied in two groups: medical specialists (oncologists and 
cardiologists) and observers in the NLHS committee. Participants in each group 
were anonymously asked to choose five of ten suggested technologies from the list 
of technologies submitted for inclusion in the 2012 NLHS and rank them accord-
ing to importance. Subsequently, the participants repeated the experiment after 
receiving aggregated feedback on the relative ranking of each technology within the 
same group after the first round. Comparison of the results was performed using 
descriptive statistics and non-parametric tests. Results: After two rounds of the 
experiment, observers and medical specialists reached agreement on four of the 
five highest ranked technologies in each field (oncology and cardiology) regarding 
their importance to be included in the NLHS. Three of these four technologies were 
indeed included in the NLHS for 2012. ConClusions: The Delphi method is one of 
the best-known techniques to control group interaction and reach a consensus by 
utilizing the expertise of committee members. The study demonstrated the feasibil-
ity using the Delphi method for ranking health care technologies.
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objeCtives: In the lack of head-to-head comparative trials to demonstrate the effi-
cacy of new treatments, it is common to use network meta-analysis (NMA), includ-
ing indirect treatment comparison (ITC) or combine direct and indirect evidence 
through mixed treatment comparison (MTC). Due to the increasing number of drugs 
approved for the same indication and the increasing complexity of networks for 
treatments comparisons, new methods of MTC taking into account all the com-
parisons have aroused. Health Technology Assessment (HTA) bodies increasingly 
demand NMA although different recommendations about the methodologies to be 
applied exist. This study aims to review recommendations regarding ITCs and MTCs 
among the main HTA bodies. Methods: A review of methodologies for drug com-
parison recommended by the main HTA bodies was performed. Recommendations 
related to evidence identification methods, assessment of homogeneity of studies 
and populations to be combined and statistical approach for the analysis were also 
reviewed. Results: A systematic literature search is a prerequisite for most HTA bod-
zations studied. The transparency index scores were as follows: Institut für Qualität 
und Wirtschaftlichkeit im Gesundheitswesen/Gemeinsamen Bundesausschusses 
(Germany), National Institute for Health and Care Excellence (UK), pan-Canadian 
Oncology Drug Review (Canada), Common Drug Review (Canada), Pharmaceutical 
Benefits Advisory Committee (Australia), Comissão Nacional de Incorporação 
de Tecnologias (Brazil), Haute Autorité de Santé (France), Agencia de Evaluación 
de Tecnologias Sanitarias (Spain), and Agenzia Italiana del Farmaco (Italy) were 
97%, 96%, 91%, 83%, 78%, 70%, 67%, 53%, and 25%, respectively. ConClusions: 
Transparency amongst HTA organizations is progressively becoming the interna-
tional standard. However, the extent of transparent processes and procedures proves 
to be heterogeneous amongst international review organizations.
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objeCtives: Health technology assessment (HTA) agencies use an incremental 
cost-effectiveness ratio (ICER) threshold generally understood to be £30,000 for NICE 
(England), £20,000 for the SMC (Scotland), CAN$50,000 for CADTH (Canada), and 
AUS$42,000 for PBAC (Australia). To help inform future submissions, we assessed 
the rationale provided by the four HTA agencies when submissions were rejected 
despite the reported ICERs being lower than these thresholds. Methods: All HTA 
appraisals from January 2000 to May 2013 from NICE, SMC, CADTH, and PBAC were 
included in the analysis. Multiple technology appraisals, resubmissions, vaccination 
programmes, requests for advice, and submissions for which an ICER could not be 
determined were excluded from the analysis. The full responses of the remaining 
appraisals were reviewed, with the submitted ICER, recommendation, and reason-
ing behind the recommendation extracted. Results: A total of 594 submissions 
met the inclusion criteria. 354 submissions across the four HTA bodies included a 
lower-than-threshold ICER, with 107 (30.2%) of these submissions rejected. Across 
the agencies, the most common reasons for rejection were use of an inappropriate 
patient population or comparator (45/107), uncertainty regarding the clinical ben-
efits (32/107), and use of economic evidence that was not sufficiently robust (40/107). 
The reasons for rejection were consistent across the four agencies, with a similar 
proportion basing their decision at least partly on one of the three reasons provided 
above: NICE (92.9%), SMC (92.0%), CADTH (93.3%), PBAC (93.8%). ConClusions: A 
large proportion of submissions were rejected despite ICERs below the threshold. 
In instances where decisions went against the ICER thresholds, there was a clear 
tendency for identifiable problems with the clinical and economic assumptions to 
diminish the reliability of the ICERs presented. This result highlights that a lower-
than-threshold ICER is not enough for a positive recommendation and manufac-
turers must support their submission with accurate and reliable data to achieve a 
favourable outcome.
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objeCtives: A new drugs’ innovation benefit is commonly evaluated, both in 
Europe and the USA. Most of the new pharmaceutical launches have to be evalu-
ated on the level of innovation that they offer as part of the market access process. 
The objective of this abstract is to give an example of the variability that emerges 
in the innovation scores given by the Italian agency, AIFA, as compared to those of 
France, Germany and the USA. Methods: Drugs listed on the AIFA website as show-
ing potential or important innovation, were used as a benchmark to measure how 
innovation benefit assessments performed in France, Germany and the USA deviate. 
The innovation benefit was measured through: the ASMR score (Amélioration du 
Service Médical Rendu) in France, as published on the HAS website (Haute Autorite’ 
de Sante’); the level of additional benefit in Germany, as published on the G-BA 
website (Gemeinsame Bundesausschuss); the type of approval procedure as pub-
lished on the FDA (Food and Drug administration) website. In the case of the USA, 
standard approval vs. priority review was used as a proxy measure of the level of 
innovation. Results: The results of the innovation benefit’s evaluations performed 
in France, Germany and the USA differ from those performed by AIFA in 74%, 33% 
and 58% of cases respectively. The lower percentage in Germany is due to lim-
ited available information compared to other markets. ConClusions: The level 
of variability that exists between the outcomes of the innovativeness evaluation 
performed in different countries suggests that although the definition of innova-
tion may appear straightforward, it is open to different interpretations by different 
health care systems.
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objeCtives: The National Institute for Health and Care Excellence (NICE) estab-
lished the Single Technology Appraisal (STA) programme to evaluate the clinical 
and cost-effectiveness of medical technologies and provide mandatory guidance 
on how they should be used within the National Health Service (NHS) in the UK. The 
objective of this analysis is to explore how NICE advice differs between preliminary 
and final guidance in the STA process and identify actions manufacturers could 
take to increase their chances of a successful submission. Methods: For STAs 
published between February 2010 and May 2013, the appraisal consultation docu-
ment (ACD) and final appraisal determination (FAD) were identified. The guidance 
issued in these documents was compared and contrasted, and the key clinical and 
economic evidence that affected recommendations were extracted into an Excel 
